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Abstract 
 
This study has explored the role of the pneumococcal toxin, pneumolysin (Ply), in 
activating  human platelets. Following exposure to Ply [10–80 nanograms (ng)/ml], 
platelet activation and cytosolic Ca2+ concentrations were measured flow 
cytometrically according to the level of expression of CD62P (P-selectin) and 
spectrofluorimetrically respectively. Exposure to Ply resulted in marked upregulation 
of expression of platelet CD62P, achieving statistical significance at concentrations 
of 40 ng/ml and higher (p<0.05), in the setting of increased  influx of Ca2+. These 
potentially pro-thrombotic actions of Ply were attenuated by depletion of Ca2+ from 
the extracellular medium, or by exposure of the cells to a pneumolysoid devoid of 
pore-forming activity. These findings are consistent with a mechanism of Ply-
mediated platelet activation involving sub-lytic pore formation, Ca2+ influx, and 
mobilization of CD62P-expressing !-granules, which, if operative in vivo, may 
contribute to the pathogenesis of associated acute lung  and myocardial injury during 
invasive pneumococcal disease. 
 
Keywords: calcium, CD62P, community-acquired pneumonia, pneumococcus, P-
selectin, Streptococcus pneumoniae 
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Introduction 
Despite significant advances in diagnosis, care and therapy, bacterial community-
acquired pneumonia (CAP), of which Streptococcus pneumoniae (also known as the 
pneumococcus) is the major causative pathogen, continues to carry an unacceptably 
high mortality rate ranging from 5-50% [1]. Acute lung injury and multi-organ 
dysfunction syndrome, as well as acute cardiac events mostly occurring early in the 
course of CAP, have been identified as being significant contributors to mortality [1-
7]. In the case of pneumococcal CAP, an increasing body of evidence, derived from 
both clinical and experimental studies, has implicated the major cytolytic, cholesterol-
binding, pore-forming protein toxin, pneumolysin (Ply), in the pathogenesis of 
associated adverse pulmonary and cardiovascular events [8-13]. Although these 
harmful activities of Ply have been attributed to direct pulmonary and cardiac toxicity, 
it is noteworthy that Ply also possesses pro-inflammatory activities [14]. These are 
evident at lower, sub-lytic concentrations of the toxin and may also contribute to the 
pathogenesis of acute lung and cardiac injury in CAP.   
 
Importantly, platelets are now recognized to be key players in orchestrating 
inflammatory responses [15], with platelet activation seemingly associated with acute 
lung injury in the experimental setting [9] and with myocardial infarction, worsening 
heart failure or arrhythmias in the clinical setting of invasive pneumococcal disease 
[16]. To our knowledge, however, only one previous study has addressed the direct 
involvement of Ply in mediating platelet activation, documenting aggregation of these 
cells following exposure to very high concentrations of the toxin, but without 
characterizing the mediators and mechanisms involved [17].  
 
In the current study, we report on the effects of brief exposure of human platelets to 
Ply, at concentrations representative of severe pneumococcal disease [18], on  
expression of CD62P (P-selectin), as well as on influx of extracellular Ca2+, an event 
which precedes and is a prerequisite for platelet activation. In this context, CD62P is 
widely recognized as being the major platelet-derived mediator of homotypic as well 
as heterotypic aggregation, the latter involving neutrophils and endothelial cells, 
activities which are both pro-inflammatory and pro-thrombotic [16,19]. 
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Materials and Methods 
 
Permission to draw blood from healthy, adult human volunteers was granted by the 
Research Ethics Committee, Faculty of Health Sciences, University of Pretoria.  
 
Recombinant Ply and the pneumolysoid, delta6Ply, attenuated in respect of pore-
forming activity, were prepared as described previously [20, 21]. The possible 
influence of contaminating endotoxin was excluded in both Ply preparations using 
the Endosafe®-PTSTM system (Charles River Laboratories, Wilmington, MA, USA) 
which is based on the Limulus amebocyte lysate kinetic chromogenic method. Both 
active Ply and delta6Ply contained <1 endotoxin unit (EU)/microgram of protein after 
purification (1 EU is the lower limit of detection). 
 
Unless stated otherwise all other chemicals and reagents were purchased from the 
Sigma Chemical Co., St Louis, MO., USA. 
 
To prepare platelet-rich plasma (PRP), blood (anti-coagulated with 5 units/ml 
preservative-free heparin) was centrifuged at 1,000 rpm for 10 min at room 
temperature within 15 min of venepuncture and used immediately. PRP (10µl) in a 
final volume of 1ml Hanks’ balanced salt solution (HBSS, indicator-free, 1.25 mM 
calcium, pH 7.4) was incubated for 5 min at 37°C after which  one of the following 
was added: i) HBSS (control); ii) recombinant, endotoxin-free Ply (10, 20, 40, 80 
ng/ml); iii) Ply (40 ng/ml) in Ca2+-free HBSS; iv) inactive, recombinant delta6Ply (80 
ng/ml); v) the conventional platelet activator, adenosine diphosphate (ADP, 100 m") 
as a positive control system; or vi) platelet-activating factor (PAF, 400 nM) as an 
additional positive control system. The platelets were then incubated for a further 5 
min period after which flow cytometric analyses were performed to determine CD62P 
expression. 
   
The platelet suspensions (median concentration 3.2 x 106/ml, range 2,2 to 4.4 x 
106/ml) were stained with 5 #l mouse anti-human CD42a-PE-labelled (Beckman 
Coulter, Miami, USA) and 5 #l mouse anti-human CD62P-FITC-labelled (Becton 
Dickenson, Franklin Lakes, USA) monoclonal antibodies to detect the total and 
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activated platelet populations respectively. After 15 minutes of incubation in the dark, 
the samples were analysed on a Gallios flow cytometer (Beckman Coulter) and the 
results expressed as the percentage of activated platelets with 50,000 cells 
interrogated during each measurement. 
 
The Ca2+, cell-permeant, fluorescent probe, fura-2/AM, was used to measure 
alterations in platelet cytosolic Ca2+ following exposure of the cells to Ply. Briefly, 
platelet-rich plasma, prepared as described above, was incubated with fura-2/AM (4 
µM) for 45 min at 37°, and washed in PBS with ethylene glycol tetraacetic acid 
(EGTA, 3 mM). The platelets were resuspended in HBSS containing 0.1% bovine 
serum albumin  and held at room temperature until used.  
 
The fura-2-loaded cells (1-2 x 107/ml) were preincubated for 5 min at 37°C, after 
which they were transferred to disposable reaction cuvettes, which were maintained 
at 37°C in a Hitachi 650 10S fluorescence spectrophotometer with excitation and 
emission wavelengths set at 340 and 500 nm respectively. After a stable baseline 
was obtained (± 1 min), Ply (40 and 80 ng/ml) in the presence or absence of EGTA 
(3 mM), the pneumolysoid, delta6Ply, or ADP (100 #M), was added to the platelet 
suspension and the subsequent alterations in fura-2 fluorescence monitored over a 
10 min time period. 
 
Expression and statistical analysis of results 
  
The results of the flow cytometric measurement of CD62P are expressed as the 
median values with interquartile ranges (10 separate experiments using blood from 5 
different donors). Statistical analyses were performed using GraphPad Prism 5 
(GraphPad Software, San Diego, USA) using  a one-way ANOVA with a Bonferroni 
correction for multiple comparisons. The results of the experiments designed to 
measure alterations in platelet cytosolic Ca2+ are shown as the individual traces from 
a single representative experiment (6 in the series using cells from 3 separate 
donors).     
 
 
'"
"
Results 
 
As shown in Figure 1, exposure of platelets to Ply caused a dose-related increase in 
the expression of CD62P, which achieved statistical significance at concentrations of 
40 ng/ml and higher of the toxin (P<0.05), reaching levels comparable to those 
observed with PAF, but less than that  with ADP. These effects of Ply were partly 
attenuated by depletion of Ca2+ from the cell-suspending medium, while the 
pneumolysoid, delta6Ply, was relatively ineffective.  
 
The effects of exposure of platelets to Ply on cytosolic Ca2+ concentrations are 
shown in Figure 2. Treatment of platelets with Ply at concentrations of 40 or 80 ng/ml 
was accompanied by influx of Ca2+, which following a short lag period, increased 
from basal levels of 29 (IQR= 23-37) nM to peak concentrations of 84(IQR= 68-100) 
and 146 (IQR= 120-159) nM, respectively (P <0.05 for comparison of the basal 
values with the corresponding peak values following addition of Ply). The peak 
cytosolic Ca2+ concentrations did not decline for the full duration that fluorescence 
intensity was monitored. Inclusion of EGTA in the cell-suspending medium abolished 
the Ply-mediated influx of Ca2+, while the pneumolysoid, delta6Ply, was ineffective.  
An abrupt increase in fluorescence intensity which rapidly declined to basal levels 
was observed in the presence of ADP, indicative of a transient increase in cytosolic 
Ca2+ concentrations (results not shown). 
 
 
Discussion 
 
These findings demonstrate that exposure of human platelets to Ply at 
concentrations ranging from 40–80 ng/ml in vitro results in significant upregulation of 
expression of CD62P, a marker of platelet activation. These concentrations of Ply 
are of probable pathologic relevance being somewhat lower than those measured in 
the cerebrospinal fluid of patients with confirmed pneumococcal meningitis [18]. The 
attenuation of Ply-mediated platelet activation observed when the cells were 
suspended  in Ca2+-free medium, or following exposure to the pneumolysoid, 
delta6Ply, are consistent with the requirement for pore formation and influx of 
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extracellular Ca2+ in  upregulation of expression of CD62P. This contention is 
strongly supported by the finding that exposure of platelets to Ply, but not to 
delta6Ply, resulted in significant influx of Ca2+ which was abolished by depletion of 
Ca2+ from the cell-suspending medium. Unlike the immediate increases in cytosolic 
Ca2+ which were evident following receptor-mediated activation of platelets with 
ADP, Ply-mediated influx of the cation occurred after a short lag phase, reaching 
peak responses that remained elevated and did not decline to basal levels in 
keeping with the pore-forming mechanism of activity of Ply. 
 
This study has focused on CD62P because upregulation of expression of this 
adhesion molecule on platelets is increasingly recognized as being a key mediator of 
inflammatory events, directing neutrophil trafficking and activation [15]. More 
recently, CD62P has also been reported to be the primary mediator of heterotypic 
platelet-neutrophil aggregation [19], a central event in the pathogenesis of arterial 
thrombogenesis [22]. The mechanism of Ply-mediated platelet activation appears to 
involve sublytic pore formation and influx of Ca2+, resulting in mobilization of CD62P-
expressing !-granules.                        
 
Notwithstanding the previously documented direct, cytotoxic activities of Ply [8-13], 
the results of the current study are consistent with the existence of an additional 
potential mechanism of toxin-mediated acute adverse pulmonary and cardiac events, 
viz. platelet activation, which remains to be established in the clinical setting 
Nonetheless, these novel findings raise the important issue of the therapeutic 
potential of Ply- and platelet-directed therapies in the prevention or attenuation of 
pneumococcal CAP-related cardiac morbidity and mortality. 
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Figure Legends 
 
Figure 1: Box - and – whisker plots showing the effects on platelet activation, 
measured according to the percentage of cells expressing CD62P, of: i) pneumolysin 
(Ply) at concentrations of 10, 20, 40, 80 ng/ml; ii) Ply (40 ng/ml) in Ca2+-free medium 
(Ca f); iii) delta6Ply (80 ng/ml); and iv) ADP (100 µM) and PAF (400 nM) as positive 
controls. The results of 10 experiments are expressed as the median values with 
interquartile ranges (25-75%). 
*P<0.05 
 
Figure 2: The effects of pneumolysin (          ) at a concentration of 40 ng/ml only on 
the influx of Ca2+ into platelets measured according to an increase in fluorescence 
intensity of intracellular fura-2/AM are shown in A;  those of Ply  at 80 ng/ml  in the 
absence  (         ) or presence of EGTA (-- -- --) are shown in B. The effects of active 
Ply (         ) in comparison with those of the pneumolysoid delta6Ply  (!!!!!!!!!) at a 
concentration of 80 ng/ml are shown in C.  Ply and delta6Ply were added as 
indicated by the arrow. These traces are from a single representative experiment (6 
in the series). 
 
 
 
 
 
